Accessibility Menu
Silexion Therapeutics logo

Silexion Therapeutics(NASDAQ) SLXN

Market Cap$2.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-98%
1 Month-16%
$2.52
+11.01%
+0.25Today
Silexion Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.272026-07-24
Silexion Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-12.02%USD 2.582026-07-17
1 month-15.93%USD 2.702026-06-24
3 month-71.01%USD 7.832026-04-24
Year to date-88.18%USD 19.202025-12-31
1 year-98.2%USD 126.302025-07-24
3 year-99.98%USD 14,350.372023-07-25
5 year-99.98%USD 13,027.502021-07-23
Since inception-99.98%USD 13,500.002021-04-07

Silexion Therapeutics Financials at a Glance

Market Cap

$2.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$12.91M

EPS (TTM)

-$94.56

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

0.73 (Low)

Price

$2.52

Volume

34,762.012

Open

$2.31

Previous Close

$2.27

Daily Range

$2.30 - $2.54

52-Week Range

$2.20 - $223.60

Estimated Earnings Date

Aug 11, 2026

SLXN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Silexion Therapeutics

Silexion develops medicines for people with hard-to-treat cancers. Its main products aim to stop cancer growth by targeting faulty genes. These treatments are designed for patients with pancreatic, prostate, and brain tumors.

What’s in the Silexion Toolbox?

  • SIL204: Second-generation therapy targeting multiple KRAS gene mutations in solid tumors; preclinical and regulatory stages; 0% of revenue.
  • siG12D-LODER: Extended-release treatment for pancreatic cancer; completed early clinical trials; 0% of revenue.
  • Prostate-LODER: Preclinical therapy for prostate cancer; 0% of revenue.
  • GBM-LODER: Preclinical therapy for glioblastoma, a type of brain tumor; 0% of revenue.
  • LODER Platform: Biodegradable delivery system for targeted, slow-release cancer drugs; used in all main products.

Growth Moves: Silexion’s Expansion Playbook

  • Listed on Nasdaq in August 2024 after a business combination.
  • Started Phase 2/3 clinical trial preparations for SIL204 in 2025.
  • Expanded pipeline to include therapies for gastric and other KRAS-driven cancers in 2025.
  • Secured positive regulatory feedback in Europe and Israel in 2025.
  • Raised $11 million in public offerings and $2.6 million from warrant exercises in 2025.

Why Silexion Isn’t Just Another Biotech

Silexion targets cancer at the genetic level, aiming to silence faulty genes before harmful proteins form. Its delivery system releases medicine directly into tumors, which may help reach hard-to-treat areas. The company holds patents on its technology, providing protection through at least 2043.

Five Things You Need to Know

  • No revenue reported in 2025; company remains pre-commercial.
  • Net loss was $11.9 million in 2025, down 27.9% from 2024.
  • Research and development expenses rose 22.4% to $7.1 million in 2025.
  • Cash and cash equivalents were $6.0 million as of December 31, 2025.
  • Auditors note substantial doubt about Silexion’s ability to continue without new funding.

Bottom Line

Silexion focuses on developing gene-targeted cancer therapies using a unique delivery system. The company remains in early stages, with no product sales and ongoing funding needs.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

Ilan Hadar, MBA

Website

silexion.com

Headquarters

Ramat Gan, 5250606, IL

SLXN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-516.87%

Return on Capital

378.77%

Return on Assets

-280.53%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.06M

Volume

34.76K

Avg. Volume

641.25K

Financials (TTM)

Gross Profit

-$6.00K

Operating Income

$10.53M

EBITDA

-$12.89M

Operating Cash Flow

-$12.01M

Capital Expenditure

-$3.00K

Free Cash Flow

-$12.02M

Cash & ST Invst.

$2.41M

Total Debt

$436.00K

Silexion Therapeutics Performance Analysis

Silexion Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Silexion Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Silexion Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 52.37N/A
20232023-12-31USD -6,634.98N/A
20242024-12-31USD -3,953.62-40.4%
20252025-12-31USD -89.60-97.7%
Silexion Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-301761.5%
Q32025-09-30-33.3%
Q42025-12-31-149.0%
Q12026-03-3139.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$2.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$2.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$172.38K

N/A

Employees

14

N/A

Net Income

-$2.73M

-57.5%

EBITDA

-$2.73M

-58.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.41M

-60.8%

Total Debt

$436.00K

-87.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$251.00K

-92.5%

Short Term Debt

$185.00K

+19.4%

Return on Assets

-2.81%

N/A

Return on Invested Capital

19.43%

N/A

Free Cash Flow

-$3.65M

-48.3%

Operating Cash Flow

-$3.65M

-48.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INDPIndaptus Therapeutics, Inc.
$2.04-21.84%
ENVBEnveric Biosciences, Inc.
$1.34+3.88%
PTIXProtagenic Therapeutics, Inc.
$0.22-24.34%
SCNIScinai Immunotherapeutics Ltd.
$0.25+7.30%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.24+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About SLXN

What is the current price of Silexion Therapeutics?

Silexion Therapeutics is trading at $2.53 per share.

What is the 52-week range for Silexion Therapeutics?

Over the past 52 weeks, Silexion Therapeutics has traded between $2.20 and $223.60.

How much debt does Silexion Therapeutics have?

As of the most recent reporting period, Silexion Therapeutics reported total debt of $1.99M.

How much cash does Silexion Therapeutics have on hand?

Silexion Therapeutics reported $2.44M in cash and cash equivalents in its most recent financial results.

What is Silexion Therapeutics’s dividend yield?

Silexion Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services